WallStreetZenWallStreetZen

NASDAQ: CYTH
Cyclo Therapeutics Inc Stock

Open Broker Account
$1.99+0.20 (+11.17%)
Updated Dec 8, 2022
CYTH Price
$1.99
Fair Value Price
$4.60
Market Cap
$16.88M
52 Week Low
$0.91
52 Week High
$5.12
P/E
-1.26x
P/B
3.01x
P/S
9.19x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.77M
Earnings
-$13.26M
Gross Margin
89.2%
Operating Margin
-747.59%
Profit Margin
-747.6%
Debt to Equity
0.51
Operating Cash Flow
-$15M
Beta
0.84
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CYTH Overview

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company developing cyclodextrin-based products for the treatment of various diseases. It also sells cyclodextrins and related products to pharmaceutical and nutritional companies for use in diagnostics and specialty drugs. Known as CTD Holdings, Inc. until 2019, Cyclo Therapeutics was incorporated in 1990 and is based in Gainesville, FL.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CYTH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CYTH ($1.99) is undervalued by 56.73% relative to our estimate of its Fair Value price of $4.60 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CYTH ($1.99) is significantly undervalued by 56.73% relative to our estimate of its Fair Value price of $4.60 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CYTH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CYTH due diligence checks available for Premium users.

Be the first to know about important CYTH news, forecast changes, insider trades & much more!

CYTH News

Valuation

CYTH fair value

Fair Value of CYTH stock based on Discounted Cash Flow (DCF)
Price
$1.99
Fair Value
$4.60
Undervalued by
56.73%
CYTH ($1.99) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CYTH ($1.99) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CYTH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CYTH price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.26x
Industry
19.44x
Market
21.39x

CYTH price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.01x
Industry
1.76x
CYTH is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CYTH's financial health

Profit margin

Revenue
$452.2k
Net Income
-$4.2M
Profit Margin
-939.2%
CYTH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CYTH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$8.5M
Liabilities
$2.9M
Debt to equity
0.51
CYTH's short-term assets ($8.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CYTH's short-term assets ($8.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CYTH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CYTH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.2M
Investing
$18.3k
Financing
$0.0
CYTH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CYTH vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
CYTH$16.88M+11.17%-1.26x3.01x
SBFM$16.60M+0.96%-0.14x0.41x
SISI$17.22M+3.96%-0.73x0.48x
NLTX$17.68M+1.22%-0.39x0.17x
CLVR$19.47M-5.97%-0.22x0.28x

Cyclo Therapeutics Stock FAQ

What is Cyclo Therapeutics's quote symbol?

NASDAQ: CYTH) Cyclo Therapeutics trades on the NASDAQ under the ticker symbol CYTH. Cyclo Therapeutics stock quotes can also be displayed as NASDAQ: CYTH.

If you're new to stock investing, here's how to buy Cyclo Therapeutics stock.

What is the 52 week high and low for Cyclo Therapeutics (NASDAQ: CYTH)?

(NASDAQ: CYTH) Cyclo Therapeutics's 52-week high was $5.12, and its 52-week low was $0.91. It is currently -61.13% from its 52-week high and 118.68% from its 52-week low.

How much is Cyclo Therapeutics stock worth today?

(NASDAQ: CYTH) Cyclo Therapeutics currently has 8,481,848 outstanding shares. With Cyclo Therapeutics stock trading at $1.99 per share, the total value of Cyclo Therapeutics stock (market capitalization) is $16.88M.

Cyclo Therapeutics stock was originally listed at a price of $118.80 in May 3, 2000. If you had invested in Cyclo Therapeutics stock at $118.80, your return over the last 22 years would have been -98.32%, for an annualized return of -16.96% (not including any dividends or dividend reinvestments).

How much is Cyclo Therapeutics's stock price per share?

(NASDAQ: CYTH) Cyclo Therapeutics stock price per share is $1.99 today (as of Dec 8, 2022).

What is Cyclo Therapeutics's Market Cap?

(NASDAQ: CYTH) Cyclo Therapeutics's market cap is $16.88M, as of Dec 10, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cyclo Therapeutics's market cap is calculated by multiplying CYTH's current stock price of $1.99 by CYTH's total outstanding shares of 8,481,848.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.